TY - JOUR
T1 - Drug Target Commons
T2 - A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions
AU - Tang, Jing
AU - Tanoli, Zia-ur-Rehman
AU - Ravikumar, Balaguru
AU - Alam, Zaid
AU - Vähä-Koskela, Markus
AU - Peddinti, Gopal
AU - van Adrichem, Arjan J.
AU - Wakkinen, Janica
AU - Jaiswal, Alok
AU - Karjalainen, Ella
AU - Gautam, Prson
AU - He, Liye
AU - Parri, Elina
AU - Khan, Suleiman
AU - Gupta, Abhishekh
AU - Ali, Mehreen
AU - Yetukuri, Laxman
AU - Gustavsson, Anna-Lena
AU - Seashore-Ludlow, Brinton
AU - Hersey, Anne
AU - Leach, Andrew R.
AU - Overington, John P.
AU - Repasky, Gretchen
AU - Wennerberg, Krister
AU - Aittokallio, Tero
N1 - Funding Information:
The authors thank all the parties that have made their compound-target bioactivity data publicly available, Dr. Ola Engkvist (AstraZeneca R&D Gothenburg) for his help with the BAO assay annotations, and Kyösti Sutinen and Olle Hansson (FIMM) for their help with the DTC interface and server. This work was supported by funding from the European Union's Horizon 2020 research and innovation program 2014–2020 under grant agreement no. 634143 (MedBioinformatics to T.A.), the European Research Council (ERC) starting grant agreement no. 716063 (DrugComb to J.T.), the Academy of Finland (grants 292611 , 269862 , 272437 , 279163 , 295504 , 310507 to T.A.; 272577 , 277293 to K.W.; and 296516 to S.K.), The Sigrid Jusélius Foundation (K.W.), Cancer Society of Finland (T.A and K.W.). J.P.O. and A.H. were funded by EMBL member nation states and Wellcome Trust Strategic Awards ( WT086151/Z/08/Z and WT104104/Z/14/Z ).
Funding Information:
The authors thank all the parties that have made their compound-target bioactivity data publicly available, Dr. Ola Engkvist (AstraZeneca R&D Gothenburg) for his help with the BAO assay annotations, and Ky?sti Sutinen and Olle Hansson (FIMM) for their help with the DTC interface and server. This work was supported by funding from the European Union's Horizon 2020 research and innovation program 2014?2020 under grant agreement no. 634143 (MedBioinformatics to T.A.), the European Research Council (ERC) starting grant agreement no. 716063 (DrugComb to J.T.), the Academy of Finland (grants 292611, 269862, 272437, 279163, 295504, 310507 to T.A.; 272577, 277293 to K.W.; and 296516 to S.K.), The Sigrid Jus?lius Foundation (K.W.), Cancer Society of Finland (T.A and K.W.). J.P.O. and A.H. were funded by EMBL member nation states and Wellcome Trust Strategic Awards (WT086151/Z/08/Z and WT104104/Z/14/Z).
Publisher Copyright:
© 2017 The Authors
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/2/15
Y1 - 2018/2/15
N2 - Knowledge of the full target space of bioactive substances, approved and investigational drugs as well as chemical probes, provides important insights into therapeutic potential and possible adverse effects. The existing compound-target bioactivity data resources are often incomparable due to non-standardized and heterogeneous assay types and variability in endpoint measurements. To extract higher value from the existing and future compound target-profiling data, we implemented an open-data web platform, named Drug Target Commons (DTC), which features tools for crowd-sourced compound-target bioactivity data annotation, standardization, curation, and intra-resource integration. We demonstrate the unique value of DTC with several examples related to both drug discovery and drug repurposing applications and invite researchers to join this community effort to increase the reuse and extension of compound bioactivity data. Tang et al. launches a novel crowd-sourcing effort to standardize the collection, management, curation, and annotation of the notoriously heterogeneous compound-target bioactivity measurements. The web-based community platform aims to provide the most comprehensive, reproducible, and sustainable bioactivity knowledge base for the end users.
AB - Knowledge of the full target space of bioactive substances, approved and investigational drugs as well as chemical probes, provides important insights into therapeutic potential and possible adverse effects. The existing compound-target bioactivity data resources are often incomparable due to non-standardized and heterogeneous assay types and variability in endpoint measurements. To extract higher value from the existing and future compound target-profiling data, we implemented an open-data web platform, named Drug Target Commons (DTC), which features tools for crowd-sourced compound-target bioactivity data annotation, standardization, curation, and intra-resource integration. We demonstrate the unique value of DTC with several examples related to both drug discovery and drug repurposing applications and invite researchers to join this community effort to increase the reuse and extension of compound bioactivity data. Tang et al. launches a novel crowd-sourcing effort to standardize the collection, management, curation, and annotation of the notoriously heterogeneous compound-target bioactivity measurements. The web-based community platform aims to provide the most comprehensive, reproducible, and sustainable bioactivity knowledge base for the end users.
KW - bioassay annotation
KW - chemical biology
KW - cheminformatics
KW - community effort
KW - crowd sourcing
KW - data curation
KW - drug discovery
KW - drug repositioning
KW - drug repurposing
KW - open data
UR - http://www.scopus.com/inward/record.url?scp=85038839435&partnerID=8YFLogxK
U2 - 10.1016/j.chembiol.2017.11.009
DO - 10.1016/j.chembiol.2017.11.009
M3 - Article
C2 - 29276046
VL - 25
SP - 224-229.e2
JO - Cell Chemical Biology
JF - Cell Chemical Biology
SN - 2451-9456
IS - 2
ER -